Enedra Therapeutics develops precision medicines that leverage synthetic lethality and computational systems biology to target the genetic heterogeneity of tumors. This approach addresses the challenge of poor survival rates in cancer patients by creating personalized therapies tailored to specific tumor profiles.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer's genetic heterogeneity, driven by chromosomal instability (CIN) and point mutations, leads to poor survival rates due to tumor evolution and resistance to conventional treatments. Identifying effective drug targets that can overcome this heterogeneity remains a significant challenge. Current methods struggle to personalize therapies effectively based on the unique genetic profiles of individual tumors.
Solution
Enedra Therapeutics is developing precision medicines that target the fundamental mechanisms enabling cancer cell evolution, specifically addressing the challenges posed by tumor heterogeneity. Their approach involves identifying drug targets essential for tumor survival despite CIN, and defining patient selection markers for these targets. Enedra's platform, CASPAROV, leverages advanced computational and genomic science to discover personalized medicines effective against heterogeneous cancers. This platform aims to move from treating cancer as a heterogeneous disease to delivering personalized therapies tailored to individual tumor profiles. The company is currently developing a pipeline of programs focused on novel, cancer-agnostic targets.
Target Audience
Enedra's primary target audience includes cancer patients with heterogeneous tumors, oncologists seeking personalized treatment options, and pharmaceutical companies interested in developing precision oncology drugs.
Features
- CASPAROV platform utilizes computational systems biology and genomic science for target discovery.
- Focus on identifying drug targets essential for tumor survival despite chromosomal instability (CIN).
- Development of patient selection molecular markers to personalize treatment.
- Pipeline of programs targeting novel, cancer-agnostic targets at the discovery stage.
- Aims to create precision medicines effective against the biological complexity of heterogeneous cancers.